Program
OPCT-001
A development code. Also written as “OpCT-001”.
Its studies are mostly in Usher Syndromes, led by Bayer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 11 open or running | phase 2since Jan 17, 2025 | Jan 17, 2025 | Oct 2029phase 2 · NCT06789445 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2025First study: phase 2 study in Retinitis PigmentosaFirst studyNCT06789445 · 54 planned · United States
Ahead
- Oct 2029Primary completion: phase 2 study in Retinitis PigmentosaNCT06789445
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06789445Retinitis Pigmentosa · United States | 2 | Recruiting | Oct 2029 | 54 |
How it is read
Names in the registry
- “OpCT-001”, 2 entries
Codes read as this program: OPCT001.
Conditions, from the studies’ own filings
- Usher Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.